Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDSyndax Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 3 | -$2.45 | -$0.05 | -$0.98 |
| Q2 2024 | 6 | -$2.28 | -$0.05 | -$0.91 |
| Q3 2024 | 3 | -$2.67 | -$0.06 | -$1.07 |
| Q4 2024 | 9 | -$16.24 | $5.32 | -$1.00 |
| Q1 2025 | 3 | -$1.10 | -$1.01 | -$1.05 |
| Q2 2025 | 2 | -$2.61 | -$0.06 | -$1.04 |
| Q3 2025 | 2 | -$2.51 | -$0.06 | -$1.00 |
| Q4 2025 | 2 | -$2.09 | -$0.05 | -$0.83 |
Syndax Pharmaceuticals, Inc. Earnings Date And Information
Syndax Pharmaceuticals, Inc. last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-0.98 earnings per share for the quarter, topping analysts' consensus estimates of $-1.13 by $0.15. The company had revenue of 12.50 M for the quarter and had revenue of 0 for the year. Syndax Pharmaceuticals, Inc. has generated $-3 earnings per share over the last year ($-2.98 diluted earnings per share) and currently has a price-to-earnings ratio of -3.76. Syndax Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Syndax Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/05/2024 | Q3 2024 | -$1.13 | -$0.98 | 0.15 | $9.32 M | $12.50 M |
| 08/01/2024 | Q2 2024 | -$0.91 | -$0.80 | 0.11 | $142,857 | $3.50 M |
| 05/08/2024 | Q1 2024 | -$0.96 | -$0.85 | 0.11 | $0 | |
| 02/27/2024 | Q4 2023 | -$0.99 | -$1.00 | -0.01 | $536,000 | |
| 11/02/2023 | Q3 2023 | -$0.80 | -$0.73 | 0.07 | $0 | |
| 08/03/2023 | Q2 2023 | -$0.73 | -$0.64 | 0.09 | $0 | |
| 05/08/2023 | Q1 2023 | -$0.61 | -$0.52 | 0.09 | $0 | |
| 02/28/2023 | Q4 2022 | -$0.64 | -$0.57 | 0.07 | $0 | |
| 11/03/2022 | Q3 2022 | -$0.65 | -$0.59 | 0.06 | $750,000 | $0 |
| 08/08/2022 | Q2 2022 | -$0.65 | -$0.62 | 0.03 | $1.38 M | $0 |
| 05/09/2022 | Q1 2022 | -$0.63 | -$0.64 | -0.01 | $0 | |
| 03/01/2022 | Q4 2021 | $0.28 | $1.81 | 1.53 | $126.58 M | |
| 11/15/2021 | Q3 2021 | -$0.64 | -$0.40 | 0.24 | $29.41 M | $12.38 M |
| 08/09/2021 | Q2 2021 | -$0.74 | -$0.44 | 0.3 | $225,000 | $379,000 |
| 05/11/2021 | Q1 2021 | -$0.64 | -$0.54 | 0.1 | $379,000 | |
| 03/11/2021 | Q4 2020 | -$0.44 | $380,000 | |||
| 11/05/2020 | Q3 2020 | -$0.46 | $200,000 | $379,000 | ||
| 08/06/2020 | Q2 2020 | -$0.47 | -$0.42 | 0.05 | $390,000 | $379,000 |
| 05/07/2020 | Q1 2020 | -$0.51 | -$0.44 | 0.07 | $379,000 | |
| 03/05/2020 | Q4 2019 | -$0.44 | $380,000 |
Syndax Pharmaceuticals, Inc. Earnings: FAQ's
When is Syndax Pharmaceuticals, Inc.'s earnings date?
Syndax Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
Did Syndax Pharmaceuticals, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Syndax Pharmaceuticals, Inc. (:SNDX) reported $-0.98 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.13 by $0.15.
How can I listen to Syndax Pharmaceuticals, Inc.'s earnings conference
call?
The conference call for Syndax Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
How can I read Syndax Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Syndax Pharmaceuticals, Inc.'s latest earnings report can be read online.
How much profit does Syndax Pharmaceuticals, Inc. generate each year?
Syndax Pharmaceuticals, Inc. (:SNDX) has a recorded net income of $0. Syndax Pharmaceuticals, Inc. has generated $-2.98 earnings per share over the last four quarters.
What is Syndax Pharmaceuticals, Inc.'s price-to-earnings ratio?
Syndax Pharmaceuticals, Inc. (:SNDX) has a price-to-earnings ratio of -3.76 and price/earnings-to-growth ratio is 0.51.